Homology Medicines Inc
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
QTTB$9.34+1.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| For the Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Net loss | $(112,961) | $(5,005) |
| Other comprehensive gain (loss): | ||
| Change in unrealized gain (loss) on available for sale securities, net | 399 | (397) |
| Total other comprehensive gain (loss) | 399 | (397) |
| Comprehensive loss | $(112,562) | $(5,402) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.